We see innovation as essential to our vision of being a global leader in rare diseases. We need to reinvest in research and development to continue providing innovative treatments, creating new evidence, and expanding the use of our medicines.
Major ongoing clinical studies and medicines in registration in a major region or country.
Updated: 16 July 2025.
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Every day, we work actively to find better ways to understand and meet patient needs.
Find out more about our business and financial performance.
Here we present our most recent press releases, news articles, and images.